Biotin Price Update: Sustained Growth Across Key Markets in Q1 2026

Biotin is vitamin B7, a water-soluble coenzyme. Produced almost entirely through microbial fermentation in China, it reaches buyers as pharmaceutical-grade crystals or diluted premix concentrate serving human nutrition, pharmaceutical, and animal feed markets. Biotin prices are shaped by three converging cost layers: fermentation substrate economics, energy expenditure in downstream purification, and container freight rates on Asia-origin export lanes. Dietary supplements, pharmaceutical preparations, animal feed additives, and personal care formulations compete for consistent supply volumes, while seasonal livestock and nutraceutical purchasing cycles create periodic procurement surges that amplify price sensitivity.

Global Market Overview

Globally, the biotin industry reached a volume of 662.38 Thousand Tons in 2025. Market projections indicate steady growth, with the industry expected to reach a volume of 1,000.85 Thousand Tons by 2034, with a compound annual growth rate (CAGR) of 4.69% during 2026-2034. Cosmetic biotin formats gained retail shelf presence in European and North American markets, broadening the biotin price trend sensitivity to consumer wellness purchasing cycles. Pharmaceutical utilization in dermatology and metabolic disorder management contributes a price-inelastic demand layer that moderates downside price pressure during softer consumption periods.

Biotin Price Trend Q1 2026

Regional prices (USD per MT) and QoQ changes Q1 2026 vs Q4 2025:

To access real-time prices Request Sample

What Moved Prices

USA:

• In Q1 2026, at USD 17,551/MT, biotin prices in the USA gained 0.89% QoQ. Nutraceutical distributors and feed additive compounders, having held cautious inventory positions through Q4 2025, stepped up procurement as wellness supplement orders from beauty and fitness channels firmed through February. Asian exporters cited tight prompt cargo availability and declined to discount spot offers.
• Constrained by disciplined Chinese output programs and a supplier base with minimal incentive to discount, USA importers found virtually no negotiating room as Q1 progressed. Buyers carrying lean domestic stocks could not defer procurement further into the quarter without risking supply gaps against confirmed downstream pharmaceutical and supplement orders. The biotin price chart traced a steady ascent. Pharmaceutical channel restocking and tight Asia-Pacific export supply reinforced each other simultaneously, sustaining upward momentum from January through March.

Germany:

• During Q1 2026, biotin prices in Germany climbed to USD 22,249/MT, recording a 2.87% QoQ gain. Pharmaceutical and nutritional supplement manufacturers pulled volumes forward after anticipating further supplier price revisions before quarter-end, reducing buffer stock risk at the cost of higher procurement values. European distributor stock levels stayed below buyer preference throughout.
• Across the cosmetic and personal care segment, formulators maintained steady purchase cadences alongside supplement buyers, sustaining broad-based order flow through March. Feed-grade consumption held at stable volumes, adding a reliable demand base. Slightly elevated inland European transport costs through February pressed landed values marginally higher, while constrained spot cargo availability on Asia-to-Europe shipping services left supplier negotiating leverage intact.

China:

• In Q1 2026, biotin prices in China firmed to USD 22,422/MT, up 2.34% from Q4 2025. Recovering export inquiry volumes drove the increase: international buyers replenishing depleted inventories placed orders ahead of schedule, tightening volumes available for domestic pharmaceutical and feed additive buyers. Fermentation producers declined to expand output in response to the short-term demand uptick, preserving supply discipline throughout the quarter.
• With forward offer calendars constrained at the dominant Chinese producers, domestic buyers had limited recourse beyond accepting prevailing terms. CNY/USD stability removed the currency-driven negotiating angle many importers had used in prior quarters. Spot premiums for pharmaceutical-grade material widened through February, stabilizing only once order books filled at revised price levels and supply pressure eased heading into March.

Brazil:

• During Q1 2026, biotin prices in Brazil advanced to USD 19,817/MT, a 1.98% QoQ increase. Spot cargoes cleared faster than sellers expected. Import-dependent buyers across animal nutrition, supplement, and personal care channels absorbed firmer overseas offer levels as distributor inventories, kept deliberately lean through Q4, prompted accelerated restocking from January onward, and that early buying pace cleared available parcels well ahead of seller expectations. Procurement momentum extended through February and into March without meaningful interruption.
• BRL volatility pressed landed cost calculations sharply higher, pushing importers toward pre-booked forward contracts. Freight rates on Asia-to-Brazil container corridors remained elevated relative to pre-2024 benchmarks, compressing margins for importers operating on thin spreads. São Paulo-based distributors, carrying minimal local stock, accepted Chinese supplier terms rather than risk the supply gaps that deferred procurement had produced in prior periods.

India:

• In Q1 2026, at USD 22,386/MT, biotin prices in India posted a 2.11% QoQ gain. Pharmaceutical formulation plants in Gujarat and Hyderabad clusters registered strengthened procurement as output schedules firmed after a Q4 inventory correction phase. Nutraceutical producers and feed additive compounders joined the recovery, generating broad-based demand through the quarter as overseas supplier offers stayed firm throughout.
• Supported by recovering distributor confidence, fresh inquiries accelerated through February. Nhava Sheva and Chennai port operations processed inbound cargoes at broadly normal throughput rates, though isolated vessel delays on select Asia-India services tightened prompt delivery windows. Import parity economics held firm as currency movements kept USD-denominated landed costs elevated, and buyers returning after deferral found fewer spot parcels available than expected.

Drivers Influencing the Market

Several factors continue to shape biotin pricing and market behavior:

• Pharmaceutical and Nutraceutical Sector Demand: Driven by dermatology, hair health, and metabolic disorder applications, pharmaceutical-grade biotin commands price-inelastic procurement from formulation manufacturers in Europe, North America, and India. Gummies, capsules, and fortified beverages carrying biotin reached pharmacy, e-commerce, and fitness retail shelves through 2025 and into 2026, widening the active buyer base well beyond traditional prescription channels. Seasonal wellness purchasing spikes in post-holiday Q1 periods compress available spot inventory and sharpen short-cycle pricing responses.
   
• Animal Feed and Livestock Nutrition Demand: Across poultry, swine, and dairy cattle nutrition programs, feed-grade biotin supports hoof integrity, coat quality, and metabolic efficiency as a micronutrient coenzyme. Expanding broiler and swine production in Southeast Asia and Brazil generates growing feed premix off-take. Dairy supplementation programs in India and Northern Europe maintain consistent year-round volumes. Regulatory and veterinary pressure toward antibiotic alternatives has increased micronutrient precision in feed formulations, raising standard biotin inclusion rates.
   
• Fermentation Feedstock and Production Economics: With a few commercial-scale producers globally, all based in China, output discipline sets price floors more consistently than demand cycles across most periods. Glucose substrate costs, specialty chemical precursor pricing, and energy costs in downstream purification feed directly into minimum viable selling prices. Producers pass input cost increases to buyers within weeks of experiencing them. Capacity expansion requires years and heavy capital commitment, limiting supply-side responses to prolonged demand surges.
   
• Ocean Freight and Logistics Economics: On Asia-to-Europe and Asia-to-Americas trade lanes, container shipping costs represent a material variable in biotin landed cost calculations for every import-dependent buyer. At USD 1,927 per 40ft container, Drewry's World Container Index recorded a 7% week-on-week increase in early December 2025, reflecting rate adjustments on key transpacific and Asia-Europe routes. The biotin price index across import-reliant markets adjusts alongside freight benchmarks, since landed cost recalculations reach contract price reopeners and spot offer negotiations within two to four weeks of rate movements.
   
• Trade Policy and Supply Concentration: China accounts for all commercial biotin output globally, leaving every importing market structurally exposed to a single production origin. A November 2025 Institute for Feed Education and Research (IFEEDER) report found that the USA sourced 78% of its total vitamin imports from China, with biotin import supply heavily dependent on China. Tariff adjustments, export licensing changes, or production outages at Chinese fermentation facilities carry immediate pricing and availability consequences across all importing markets, with no viable alternative supply base to absorb shortfalls.
   
• Environmental and Regulatory Compliance: Tightening emissions and wastewater standards at Chinese fermentation sites raise producer operating costs that flow into export offers within one to two production cycles. That covers the supply-side cost pressure. On the demand side, EU food contact regulations and US FDA pharmaceutical-grade purity mandates impose documentation, testing, and quality assurance costs on importers and distributors. Smaller buyers in emerging markets, initially shielded from these layers, face rising compliance pressure as export-destination requirements tighten and international regulatory harmonization progresses.

Recent Highlights & Strategic Developments

Recent strategic moves within the industry further illustrate evolving dynamics:

• In November 2025, Vyvo Therapeutics launched an expanded IV therapy service at its medical spa facility, broadening its therapeutic menu to include advanced micronutrient infusion treatments. The service incorporated vitamins including biotin as part of a broader strategy to attract health-focused clientele seeking comprehensive intravenous wellness programs.

Outlook & Strategic Takeaways

Looking ahead, the biotin market is expected to sustain consistent volume expansion through 2034 as dietary supplement consumption deepens across Asia-Pacific, pharmaceutical applications in metabolic and dermatological health expand, and livestock nutrition programs intensify across emerging production markets. Supply concentration in China and fermentation feedstock cost trajectories will remain the pivotal variables shaping the biotin price forecast across all buyer cost structures.

To navigate this complex landscape, stakeholders should:

• Monitor Regional Price Differentials: Track quarterly price variations across the USA, Germany, China, Brazil, and India to identify cost-advantaged procurement windows. Establish benchmarking protocols comparing landed costs against prevailing contract rates each quarter to systematize sourcing decisions.
   
• Assess Freight Market Developments: Monitor container spot rate indices on Asia-to-Europe and Asia-to-Americas corridors to anticipate landed cost shifts before they reach contract renegotiation stages. Build index-linked rate adjustment clauses into logistics agreements to cap exposure when Drewry WCI benchmarks spike.
   
• Evaluate Downstream Demand Indicators: Track pharmaceutical manufacturing output schedules, supplement retail sell-through data, and feed premix order books across principal consuming markets. Align procurement cycle timing with confirmed demand signals rather than speculative inventory building.
   
• Review Regulatory Compliance Expenditures: Audit testing, documentation, and quality assurance costs tied to pharmaceutical-grade and feed-grade biotin procurement across key markets. Identify supplier relationships that bundle compliance support services, reducing per-unit administrative burden without compromising certification.
   
• Strengthen Currency Exposure Management: Implement FX hedging programs for USD-denominated procurement in BRL, INR, and EUR markets, where exchange rate movements shift landed costs by 3 to 6% within a quarter. Coordinate procurement and treasury planning cycles to align coverage windows with import payment schedules.
   
• Explore Emerging Application Segments: Investigate commercial viability in biotin-fortified functional beverages, premium pet supplements, and specialty cosmetic biotechnology formulations where margin structures absorb higher input costs. Benchmarking biotin price per MT across regional supplier offers positions procurement teams to act decisively when emerging-segment volumes materialize.

Subscription Plans & Customization

IMARC offers flexible subscription models to suit varying needs:

• Monthly Updates: 12 deliverables/year
• Quarterly Updates: 4 deliverables/year
• Biannual Updates: 2 deliverables/year

Each includes detailed datasets (Excel + PDF) and post-report analyst support.